The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessAbstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,948
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
“Furthermore, EV PD-L1 levels have been associated with tumor progression (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018; Yang et al., 2018).”
Background
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. https://app.cochat.ai/papers/10.1126/sciadv.aar2766
- The paper
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., . . . Chiocca, E. A. (2018). Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances. https://doi.org/10.1126/sciadv.aar2766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.